Carlos Fernando de Magalhães Francesconi

机构：Hospital de Clínicas de Porto Alegre · ORCID：0000-0001-8206-9121

发表论文 56 篇 · 总被引 997 次 · h-index 12

代表论文

• Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial (2023 · ˜The œLancet. Gastroenterology & hepatology · 被引 242)
• Risankizumab for Ulcerative Colitis (2024 · JAMA · 被引 126)
• Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study (2024 · The Lancet · 被引 114)
• Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies (2024 · The Lancet · 被引 104)
• Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial (2021 · ˜The œLancet. Gastroenterology & hepatology · 被引 96)
• Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial (2020 · The Lancet Infectious Diseases · 被引 84)